Developer docs
API playgroundTry for free, no card

Search company profiles

Red Queen Bio

Full company profile

uuid003qfde

Namestring
Red Queen Bio
Legal namestring
Red Queen Bio
Websiteurl
redqueen.bio
Company typeenum
Private
Founded yearint
2025
Descriptiontext

Red Queen Bio is an AI biosecurity company founded in November 2025 in Boston, Massachusetts, and structured as a Public Benefit Corporation. The company was spun out by Nikolai Eroshenko and Hannu — co-founders of clinical-stage mRNA company HelixNano — after observing that frontier AI models exhibit biological creativity that cuts both ways: capable of designing breakthrough therapies, but also of conceiving novel biothreats. Red Queen Bio's stated mission is to scale biological defenses at the same rate that AI capabilities in biology advance, a thesis it calls 'defensive co-scaling.'

The company's technology stack comprises three integrated components: a Biothreat Mapping Platform that works with frontier AI labs to identify AI-enabled biological threats; a Countermeasure Design Pipeline built on frontier AI models, lab automation, and reinforcement learning, engineered to scale directly with compute; and On-Demand Biologics Manufacturing to produce identified countermeasures rapidly. A documented demonstration of the pipeline's capability is a collaboration with OpenAI in which GPT-5 autonomously iterated on molecular cloning protocols to achieve a 79-fold improvement in cloning efficiency through a novel mechanism combining RecA recombinase and phage T4 gp32 proteins. The company is committed to open collaboration with all AI labs, biopharma firms, and governments globally.

The business model is still emerging. Revenue streams are described conceptually as biosecurity countermeasure services (likely government contracts and biopharma collaborations), a financial co-scaling model drawing on catastrophic risk insurance frameworks, and collaborative research grants. Go-to-market is enterprise field sales targeting frontier AI labs, US and international governments, and biopharma companies, supplemented by policy engagement to create private-sector biosecurity investment incentives. The company closed a $15M seed round in November 2025 led by OpenAI, with participation from Cerberus Ventures, Fifty Years, and Halcyon Futures. No pricing, recurring revenue, or commercial contracts have been disclosed, and the company is pre-commercial at launch.

Short descriptiontext

Red Queen Bio is an AI biosecurity Public Benefit Corporation that maps AI-enabled biological threats alongside frontier AI labs and designs pre-built medical countermeasures using AI-driven pipelines, serving governments, AI labs, and biopharma.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI biosecurity, biothreat mapping, countermeasure design, biodefense infrastructure, on-demand biologics
Industry4 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAJAIAL
Biothreat/Biocontainment & Select Agent Public Health Laboratories
Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Laboratories & Reference Testing Networks
SECONDARYHLAGAIAD
Liquid Handling & Laboratory Automation (Pipettes, Robots, Workstations)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
AI Biosecurity
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Biosecurity Countermeasure Services
TypeSubscription Recurring
Description

The company designs and develops medical countermeasures against AI-enabled biothreats, likely through government contracts, research collaborations with AI labs and biopharma, and potentially through licensing arrangements with manufacturers.

redqueen.bio
2Financial Co-Scaling Model
TypeManaged Services
Description

Exploring catastrophic risk insurance frameworks and other safety-critical industry financial models to create sustainable revenue. Governments with flat biodefense budgets cannot solve the problem alone, so the company seeks private-sector capital incentives to co-fund biosecurity infrastructure.

redqueen.bio
3Collaborative Research Grants
TypeProfessional Services
Description

Engagement with policymakers in the US and abroad to create incentives for private-sector biosecurity investment, potentially including government grants and public-private partnerships.

redqueen.bio
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Red Queen Bio designs and develops AI-driven biodefense capabilities that map AI-enabled biological threats and pre-build medical countermeasures. Its countermeasure design pipeline is built on frontier AI models, lab automation, and reinforcement learning, and is engineered to scale directly with compute, paired with on-demand biologics manufacturing for rapid production.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 79x improvement in cloning efficiency achieved in a wet lab collaboration with OpenAI using GPT-5, through a novel mechanism combining RecA recombinase and phage T4 gp32 proteins
+1 more record
Product overview1 text field

Red Queen Bio operates as a unified AI biosecurity platform with three integrated core components: the Biothreat Mapping Platform works with frontier AI labs to identify and map AI-enabled biological threats; the Countermeasure Design Pipeline leverages leading AI models, lab automation, and reinforcement learning to design medical countermeasures; and On-Demand Biologics Manufacturing enables rapid production of these countermeasures. This integrated stack provides the technological foundation for 'defensive co-scaling'—coupling defensive compute and funding to the same technological and financial forces driving the AI capability race.

Product and service3 records
1Biothreat Mapping Platform
CategoryAI Biosecurity Platform
Description

Scalable platform that works with frontier AI labs to identify and map biological threats enabled by advanced AI capabilities, providing threat intelligence for defensive preparedness. It is intended for AI labs, biopharma companies, and government biosecurity agencies.

2Countermeasure Design Pipeline
CategoryAI Biosecurity Platform
Description

AI-driven pipeline built on frontier models, lab automation, and reinforcement learning to pre-build medical countermeasures against identified biothreats, engineered to scale directly with compute resources. It is intended for AI labs, biopharma partners, and government biodefense agencies.

3On-Demand Biologics Manufacturing
CategoryBiologics Manufacturing
Description

Manufacturing capability for producing biological countermeasures on-demand, integrated with the countermeasure design pipeline to enable rapid response to emerging threats. It is intended for biopharma collaborators and government biodefense customers.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Insitro applies ML and high-throughput biology to drug discovery, overlapping with Red Queen Bio's AI + lab automation + biologic countermeasure design stack. It is a relevant emerging player but focuses on therapeutic discovery rather than biosecurity.

TypeEmerging player
Description

Cradle uses AI for protein design and engineering, comparable to Red Queen Bio's AI-driven biologic countermeasure design capabilities. It overlaps in the AI-for-biologics category but focuses on commercial protein engineering applications.

TypeBroad incumbent
Description

Ginkgo Bioworks is a large, established synthetic biology platform with explicit biodefense programs. It overlaps with Red Queen Bio in countermeasure-relevant biologics engineering and government biodefense contracting, but operates at much broader scope.

TypeEmerging player
Description

Lumen Bioscience develops orally delivered biologic therapeutics and countermeasure candidates. It overlaps with Red Queen Bio in biologic countermeasure development and on-demand manufacturing, though with a more traditional discovery approach.

TypeDirect peer
Description

Valthos is a biosecurity-focused company also backed by OpenAI, targeting AI-related biological risks. It is the closest direct competitor to Red Queen Bio in the emerging AI biosecurity category, with overlapping mission and investor base.

TypeBroad incumbent
Description

Recursion uses AI/ML and lab automation for drug discovery at scale. It is comparable to Red Queen Bio in the AI-driven biologic discovery architecture (frontier models + wet lab + reinforcement learning), though focused on therapeutics rather than biosecurity.

TypeOthers
Description

Resilience is a biomanufacturing company focused on biologics production at scale. It is comparable to Red Queen Bio's on-demand biologics manufacturing component and could serve as a manufacturing partner or capacity provider.

TypeEmerging player
Description

Profluent develops AI foundation models for protein design, directly comparable to Red Queen Bio's use of frontier AI models for biological design. It represents an emerging AI-biologics peer with overlapping core methodology.

TypeEmerging player
Description

EvolutionaryScale builds frontier AI foundation models for biology. It is comparable in developing large-scale AI models for biological applications and could serve as either a partner or competitor to Red Queen Bio's frontier-model-based pipeline.

TypeDirect peer
Description

HelixNano is the clinical-stage mRNA company co-founded by Red Queen Bio's founders (Nikolai and Hannu). It is directly comparable in therapeutic modality (mRNA biologics) and represents the technical foundation from which Red Queen Bio spun out.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Red Queen Bio

AI Biosecurityredqueen.bio

Red Queen Bio is an AI biosecurity Public Benefit Corporation that maps AI-enabled biological threats alongside frontier AI labs and designs pre-built medical countermeasures using AI-driven pipelines, serving governments, AI labs, and biopharma.

What Red Queen Bio does

Red Queen Bio is an AI biosecurity company founded in November 2025 in Boston, Massachusetts, and structured as a Public Benefit Corporation. The company was spun out by Nikolai Eroshenko and Hannu — co-founders of clinical-stage mRNA company HelixNano — after observing that frontier AI models exhibit biological creativity that cuts both ways: capable of designing breakthrough therapies, but also of conceiving novel biothreats. Red Queen Bio's stated mission is to scale biological defenses at the same rate that AI capabilities in biology advance, a thesis it calls 'defensive co-scaling.'

The company's technology stack comprises three integrated components: a Biothreat Mapping Platform that works with frontier AI labs to identify AI-enabled biological threats; a Countermeasure Design Pipeline built on frontier AI models, lab automation, and reinforcement learning, engineered to scale directly with compute; and On-Demand Biologics Manufacturing to produce identified countermeasures rapidly. A documented demonstration of the pipeline's capability is a collaboration with OpenAI in which GPT-5 autonomously iterated on molecular cloning protocols to achieve a 79-fold improvement in cloning efficiency through a novel mechanism combining RecA recombinase and phage T4 gp32 proteins. The company is committed to open collaboration with all AI labs, biopharma firms, and governments globally.

The business model is still emerging. Revenue streams are described conceptually as biosecurity countermeasure services (likely government contracts and biopharma collaborations), a financial co-scaling model drawing on catastrophic risk insurance frameworks, and collaborative research grants. Go-to-market is enterprise field sales targeting frontier AI labs, US and international governments, and biopharma companies, supplemented by policy engagement to create private-sector biosecurity investment incentives. The company closed a $15M seed round in November 2025 led by OpenAI, with participation from Cerberus Ventures, Fifty Years, and Halcyon Futures. No pricing, recurring revenue, or commercial contracts have been disclosed, and the company is pre-commercial at launch.

Red Queen Bio firmographics

Firmographics
Name
Red Queen Bio
Legal name
Red Queen Bio
Website
https://redqueen.bio
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
11–50 employees
Short description
Red Queen Bio is an AI biosecurity Public Benefit Corporation that maps AI-enabled biological threats alongside frontier AI labs and designs pre-built medical countermeasures using AI-driven pipelines, serving governments, AI labs, and biopharma.
Ownership category
akta.pro rank

Red Queen Bio industry classification

Industry
Product category
AI Biosecurity
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAJAIAL
Biothreat/Biocontainment & Select Agent Public Health Laboratories
Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Laboratories & Reference Testing Networks
SECONDARYHLAGAIAD
Liquid Handling & Laboratory Automation (Pipettes, Robots, Workstations)

Keywords

  • AI biosecurity
  • Biothreat mapping
  • Countermeasure design
  • Biodefense infrastructure
  • On-demand biologics

Where Red Queen Bio is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Red Queen Bio business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Biosecurity Countermeasure Services: The company designs and develops medical countermeasures against AI-enabled biothreats, likely through government contracts, research collaborations with AI labs and biopharma, and potentially through licensing arrangements with manufacturers.
  2. Financial Co-Scaling Model: Exploring catastrophic risk insurance frameworks and other safety-critical industry financial models to create sustainable revenue. Governments with flat biodefense budgets cannot solve the problem alone, so the company seeks private-sector capital incentives to co-fund biosecurity infrastructure.
  3. Collaborative Research Grants: Engagement with policymakers in the US and abroad to create incentives for private-sector biosecurity investment, potentially including government grants and public-private partnerships.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels2 records

Red Queen Bio product offering

Product offering

Core offering

Red Queen Bio designs and develops AI-driven biodefense capabilities that map AI-enabled biological threats and pre-build medical countermeasures. Its countermeasure design pipeline is built on frontier AI models, lab automation, and reinforcement learning, and is engineered to scale directly with compute, paired with on-demand biologics manufacturing for rapid production.

Product overview

Red Queen Bio operates as a unified AI biosecurity platform with three integrated core components: the Biothreat Mapping Platform works with frontier AI labs to identify and map AI-enabled biological threats; the Countermeasure Design Pipeline leverages leading AI models, lab automation, and reinforcement learning to design medical countermeasures; and On-Demand Biologics Manufacturing enables rapid production of these countermeasures. This integrated stack provides the technological foundation for 'defensive co-scaling'—coupling defensive compute and funding to the same technological and financial forces driving the AI capability race.

Differentiator

Problem solved

Functional benefit

Products and services

  • Biothreat Mapping Platform Scalable platform that works with frontier AI labs to identify and map biological threats enabled by advanced AI capabilities, providing threat intelligence for defensive preparedness. It is intended for AI labs, biopharma companies, and government biosecurity agencies.
  • Countermeasure Design Pipeline AI-driven pipeline built on frontier models, lab automation, and reinforcement learning to pre-build medical countermeasures against identified biothreats, engineered to scale directly with compute resources. It is intended for AI labs, biopharma partners, and government biodefense agencies.
  • On-Demand Biologics Manufacturing Manufacturing capability for producing biological countermeasures on-demand, integrated with the countermeasure design pipeline to enable rapid response to emerging threats. It is intended for biopharma collaborators and government biodefense customers.

Quantifiable outcome

  • 79x improvement in cloning efficiency achieved in a wet lab collaboration with OpenAI using GPT-5, through a novel mechanism combining RecA recombinase and phage T4 gp32 proteins
  • +1 more outcomes

Companies that use Red Queen Bio

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Red Queen Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature4 records

Red Queen Bio partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Red Queen Bio competitors and assessment

Company assessment

Emerging players

  • Insitro: Insitro applies ML and high-throughput biology to drug discovery, overlapping with Red Queen Bio's AI + lab automation + biologic countermeasure design stack. It is a relevant emerging player but focuses on therapeutic discovery rather than biosecurity.
  • Cradle Bio: Cradle uses AI for protein design and engineering, comparable to Red Queen Bio's AI-driven biologic countermeasure design capabilities. It overlaps in the AI-for-biologics category but focuses on commercial protein engineering applications.
  • Lumen Bioscience: Lumen Bioscience develops orally delivered biologic therapeutics and countermeasure candidates. It overlaps with Red Queen Bio in biologic countermeasure development and on-demand manufacturing, though with a more traditional discovery approach.
  • Profluent Bio: Profluent develops AI foundation models for protein design, directly comparable to Red Queen Bio's use of frontier AI models for biological design. It represents an emerging AI-biologics peer with overlapping core methodology.
  • EvolutionaryScale: EvolutionaryScale builds frontier AI foundation models for biology. It is comparable in developing large-scale AI models for biological applications and could serve as either a partner or competitor to Red Queen Bio's frontier-model-based pipeline.

Broad incumbents

  • Ginkgo Bioworks: Ginkgo Bioworks is a large, established synthetic biology platform with explicit biodefense programs. It overlaps with Red Queen Bio in countermeasure-relevant biologics engineering and government biodefense contracting, but operates at much broader scope.
  • Recursion Pharmaceuticals: Recursion uses AI/ML and lab automation for drug discovery at scale. It is comparable to Red Queen Bio in the AI-driven biologic discovery architecture (frontier models + wet lab + reinforcement learning), though focused on therapeutics rather than biosecurity.

Direct peers

  • Valthos: Valthos is a biosecurity-focused company also backed by OpenAI, targeting AI-related biological risks. It is the closest direct competitor to Red Queen Bio in the emerging AI biosecurity category, with overlapping mission and investor base.
  • HelixNano: HelixNano is the clinical-stage mRNA company co-founded by Red Queen Bio's founders (Nikolai and Hannu). It is directly comparable in therapeutic modality (mRNA biologics) and represents the technical foundation from which Red Queen Bio spun out.

Others

  • National Resilience: Resilience is a biomanufacturing company focused on biologics production at scale. It is comparable to Red Queen Bio's on-demand biologics manufacturing component and could serve as a manufacturing partner or capacity provider.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Red Queen Bio social profiles

Digital presence

Red Queen Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Red Queen Bio leadership team

Management profile

Number of profiles

Profiles2 records

Red Queen Bio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Red Queen Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Red Queen Bio

What does Red Queen Bio do?

Red Queen Bio designs and develops AI-driven biodefense capabilities that map AI-enabled biological threats and pre-build medical countermeasures. Its countermeasure design pipeline is built on frontier AI models, lab automation, and reinforcement learning, and is engineered to scale directly with compute, paired with on-demand biologics manufacturing for rapid production.

Is Red Queen Bio a public or private company?

Red Queen Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Red Queen Bio founded?

Red Queen Bio was founded in 2025. It employs 11 to 50 people.

Where is Red Queen Bio based?

Red Queen Bio is headquartered in Boston, United States, in the North America region.

How does Red Queen Bio make money?

Three revenue lines are on record. Biosecurity Countermeasure Services are the primary driver. The others are financial Co-Scaling Model and collaborative Research Grants.

Who are Red Queen Bio's main competitors?

Emerging players on record are Insitro, Cradle Bio, Lumen Bioscience, Profluent Bio and EvolutionaryScale. Broad incumbents are Ginkgo Bioworks and Recursion Pharmaceuticals. Direct peers are Valthos and HelixNano. National Resilience is listed as an others.

Does Red Queen Bio have an API?

No public API is recorded for Red Queen Bio.

What industry is Red Queen Bio in?

Red Queen Bio's product category is AI Biosecurity. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
citybizRed Queen Bio Appoints Ian Watson Chief Government Affairs OfficerRed Queen Bio appointed Ian Watson as Chief Government Affairs Officer, bringing decades of biodefense and federal policy experience. He will oversee government affairs strategy and expand relationships with federal agencies, including the Department of War, Energy, and Health and Human Services. The appointment supports the company's AI-enabled biosecurity technology development.citybizRed Queen Bio Appoints Ian Watson Chief Government Affairs OfficerRed Queen Bio appointed Ian Watson as Chief Government Affairs Officer, bringing decades of biodefense and federal policy experience. He will oversee government affairs strategy and expand relationships with federal agencies, including the Departments of War, Energy, and Health and Human Services. The appointment supports the company's AI-enabled biosecurity technology development.The Next WebOpenAI-backed Red Queen Bio designs antibodies with AIRed Queen Bio, an OpenAI-backed biosecurity startup, raised $36 million to design antibody drugs against viruses. It plans first clinical trials in 2027, targeting bird flu and later coronaviruses and Ebola-like viruses. The company uses AI to design antibodies that bind tightly to viral targets.YahooCould AI Stop the Next Pandemic Before It StartsRed Queen Bio is developing AI-designed antibody drugs to counter emerging viruses, aiming to create defenses before pandemics. The OpenAI-backed company raised $36 million, targeting bird flu and other threats, with first clinical trials planned for 2027. It plans to expand to coronaviruses, Ebola-like viruses, and smallpox relatives.TheStreet.comOpenAI’s new AI cuts both ways on biological threatsOpenAI launched Rosalind Biodefense on May 29, 2026, giving vetted researchers and government agencies free access to its GPT-Rosalind biology model. The company warned in June 2025 that its next-generation models could raise biological weapon risks, and the program is part of its defensive acceleration strategy. The next test is whether rivals will respond with similar biodefense programs.RdworldonlineNew survey shows just 1% report AI’s value in the wet labThe Pistoia Alliance survey found only 1% of professionals report AI's value in the wet lab, while 30% of organizations claim enterprise-wide AI rollout but 69% lack metrics on cost or timeline impact. The data was collected at a London conference, with 59% of companies citing data quality as a priority.Crunchbase NewsIntersection Of Biosecurity And AI Sees Seed-Stage SpikeTwo AI biosecurity startups, Valthos and Red Queen Bio, have raised seed funding with OpenAI participating as an investor, securing $30 million and $15 million respectively. The article frames these investments as relatively modest compared to the $110 billion OpenAI raised recently, yet represents a growing startup vertical addressing AI-enabled biological threats. SecureBio, a nonprofit focused on pandemic preparedness, also received $1.4 million in grant funding from Coefficient Giving in December.VoiceofalexandriaAbTherx and Red Queen Bio Partner on Therapeutic Antibody DiscoveryAbTherx announced a therapeutic antibody discovery partnership with Red Queen Bio, combining AbTherx's Atlas Full Human Diversity Transgenic Mouse platform with Red Queen Bio's AI-driven antibody development pipeline. The collaboration has already generated initial in vivo antibody data within three months, with Red Queen Bio holding rights to develop and commercialize resulting therapeutic antibodies while AbTherx receives research payments, development milestones, and royalty payments. The partnership leverages Red Queen Bio's mRNA and AI capabilities with AbTherx's transgenic technology for antibody candidate generation targeting biodefense and national biosecurity applications.AxiosExclusive: GPT-5 demonstrates ability to do novel lab workOpenAI's GPT-5 has demonstrated for the first time that it can perform novel laboratory work, collaborating with biosecurity startup Red Queen Bio to optimize a standard molecular cloning protocol by 79x efficiency through iterative wet lab experiments. The AI model suggested protocol improvements, received experimental results from human scientists, and proposed new protocols in a cycle that showed "glimpses of creativity" beyond simply pulling from published research. Researchers describe the findings as early but anticipate a future where AI-augmented experimentation becomes routine in scientific discovery workflows.OpenAIMeasuring AI’s capability to accelerate biological research in the wet labOpenAI collaborated with Red Queen Bio to evaluate GPT-5's capabilities in optimizing molecular cloning protocols in a wet lab setting, achieving a 79-fold improvement in cloning efficiency by introducing a novel mechanism combining RecA recombinase and phage T4 gp32 proteins. The AI autonomously proposed, analyzed, and iterated on protocol modifications over multiple experimental rounds, with scientists only carrying out the physical procedures and uploading data. The research, conducted with biosecurity safeguards, demonstrates early potential for AI to accelerate biological experimentation, though the findings remain specific to the controlled experimental system used.